Abzil

Abzil is a South Korean biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary AbZLink platform. The AbZLink technology allows for site-specific conjugation to "off-the-shelf" native antibodies without requiring genetic engineering, significantly streamlining the ADC development process. By producing homogeneous drug-to-antibody ratios (DAR), Abzil aims to enhance the stability, safety, and efficacy of cancer therapeutics. The company's internal pipeline targets validated oncology markers such as HER2 and TROP2, while also seeking partnerships to apply its platform to diverse antibody candidates. Abzil's approach is designed to overcome the limitations of traditional random conjugation, which often results in heterogeneous mixtures with suboptimal pharmacological properties.